Views & Analysis Highs and lows in regenerative medicine How developments in gene editing and screening technology are advancing regenerative medicine.
News EU regulators back blood cancer stem cell therapy Molmed's treatment aims to prevent reduce risk of graft-versus-host disease.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
